Back to Search
Start Over
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study
- Source :
- JOURNAL OF INFECTIOUS DISEASES, Journal of Infectious Diseases, Journal of Infectious Diseases, Oxford University Press (OUP), 2019, 220 (2), pp.195-202. ⟨10.1093/infdis/jiz078⟩, The Journal of Infectious Diseases
- Publication Year :
- 2019
-
Abstract
- In 2015, favipiravir was administered on a compassionate-use basis to patients with Ebola virus disease in Guinea. This study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.<br />Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. Methods To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome. Results The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors. Conclusions Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.
- Subjects :
- Compassionate Use Trials
Male
0301 basic medicine
viruses
Kaplan-Meier Estimate
Disease
medicine.disease_cause
epidemic
0302 clinical medicine
CHEMISTRY
Immunology and Allergy
030212 general & internal medicine
Child
Univariate analysis
Middle Aged
Viral Load
Ebolavirus
ddc
3. Good health
Infectious Diseases
Child, Preschool
Pyrazines
Viruses
Female
mobile laboratory
Life Sciences & Biomedicine
Adult
medicine.medical_specialty
Adolescent
Immunology
Ebola virus disease
Favipiravir
DIAGNOSIS
Antiviral Agents
Microbiology
Major Articles and Brief Reports
Young Adult
03 medical and health sciences
SIERRA-LEONE
Internal medicine
medicine
Humans
In patient
ddc:610
Retrospective Studies
Cycle threshold
Science & Technology
Ebola virus
business.industry
Retrospective cohort study
Hemorrhagic Fever, Ebola
Amides
Filovirus
VIRAL LOAD
030104 developmental biology
Blood chemistry
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Guinea
610 Medizin und Gesundheit
business
Subjects
Details
- Language :
- English
- ISSN :
- 00221899 and 15376613
- Database :
- OpenAIRE
- Journal :
- JOURNAL OF INFECTIOUS DISEASES, Journal of Infectious Diseases, Journal of Infectious Diseases, Oxford University Press (OUP), 2019, 220 (2), pp.195-202. ⟨10.1093/infdis/jiz078⟩, The Journal of Infectious Diseases
- Accession number :
- edsair.doi.dedup.....e82b8acb3a37901ef1f93dc953e3b506